PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 29, 2025

Clinical, Bone Mineral Density and Spinal Remodelling Responses to Zoledronate Treatment in Chronic Recurrent Multifocal Osteomyelitis.

View Full Paper
Ask AI
Bookmark
Share

Authors

FPFahim PatelPDP.D. DavisNCNicola Crabtree

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows improvement in bone mineral density and pain management in CRMO, indicating potential for bisphosphonates.

Key Points

  • An 88% improvement in pain was reported among patients with chronic recurrent multifocal osteomyelitis treated with zoledronate.
  • The median first-year increase in lumbar spine bone mineral apparent density Z-score was +1.35, indicating significant bone density improvement.
  • Patients commonly discontinued NSAIDs due to effective bisphosphonate therapy, with 44% stopping their use.
  • Bone density monitoring and personalized dosing of bisphosphonates are essential to avoid overtreatment in chronic recurrent multifocal osteomyelitis.

Cite This Study

Patel et al. (2025) studied this question.

synapsesocial.com/papers/68da58d1c1728099cfd10cb9https://doi.org/10.3390/diagnostics15182320
View Full Paper
Ask AI
Bookmark
Share